Investing in dividend aristocrats can form the cornerstone of a reliable investment strategy, owing to their qualities like ...
Inquirer on MSN1d
World’s first anti-depression nasal spray receives FDA approvalThe US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more potent ...
Dividend growth stocks offer a balance of stability and compounding returns, and here are three standout companies with ...
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few years now.
How can you make therapy work best for you? Here are a few tips. And a new study offers more evidence that teens are in trouble.
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Hosted on MSN11d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with itOn Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback